Sinclair is a Founder and Managing Partner at Epidarex Capital, an international life science and health technology venture fund based in Edinburgh, UK and Bethesda, MD. Epidarex funds the commercialisation of ground-breaking research and new technologies to address unmet needs in today’s healthcare market. The majority of Epidarex’s portfolio companies are spin-outs from leading research universities in the UK and US. Sinclair currently serves on the Board of Directors of Apellis Pharmaceuticals Inc., Clyde Biosciences Ltd., Edinburgh Molecular Imaging Ltd., Sirakoss Ltd and Mironid Therapeutics, Ltd. He holds an M.B.A. from Columbia Business School, an M.A. (Hons.) in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University.